Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy

•Cytopenias represent significant adverse events of chimeric antigen receptor (CAR) T cell therapy.•Increased exposure to rituximab pre-CAR T cell therapy is associated with persistent anemia and thrombocytopenia post-CAR T cell therapy.•An increased number of prior lines of therapy is associated with persistent lymphopenia and anemia post-CAR T cell therapy.